News & Views

  • Double Triumph at BPI 2014 Awards for TAP Biosystems and Merck & Co Inc `
    Richard Wales from TAP Biosystems (middle) and Dave Pollard (right) from Merck accept the BPI awards for “Best Collaboration” from BPI editor in chief Anne Montgomery
  • Mwai Ngibuini from TAP Biosystems (middle) and Dave Pollard (right) from Merck accept the BPI awards for ‘Best Technology Application - Upstream’ from BPI editor in chief Anne Montgomery

Double Triumph at BPI 2014 Awards for TAP Biosystems and Merck & Co Inc `

Nov 04 2014 Read 2166 Times

Sartorius Stedim Biotech (SSB) has announced that TAP Biosystems, part of SSB Group since 2013, and Merck & Co, Inc have won two awards at the prestigious 2014 BioProcess International (BPI) Awards. The awards recognise that the ambr250™ mini bioreactor system, developed as a result of this successful partnership, is a major breakthrough in bioprocessing technology.


At the BioProcess International Awards, TAP Biosystems and Merck won the ‘Best Collaboration Award’ beating off stiff competition from other partnerships including Invetech and Janssen. TAP Biosystems and Merck also won the ‘Best Technology Application - Upstream Award’ for the ambr250 automated mini bioreactor system against other excellent products such as the Xcellerex™ XDR-50 MO fermenter system and the MaxCyte® STX™ Scalable Transfection System.


Mwai Ngibuini, ambr250 Product Manager stated: “The main aim of our collaboration with Merck was to develop a simple to set up, single-use mini bioreactor system which has the versatility to replicate traditional bioreactors and fermenters for culturing mammalian and microbial cells. To achieve this we listened carefully to the bioprocessing experts that would use the system, as well as the context into which it would be placed and then worked tirelessly to deliver their vision.”


Ngibuini continued: “We’re delighted to win these awards with Merck because it indicates that the time and effort we all put into this partnership has really been worthwhile and the ambr250 is viewed by our bioprocess peers and experts as breakthrough technology, which has the potential to totally transform process development of antibody and protein-based therapeutics.”

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment

Digital Edition

Lab Asia August 2019

August 2019

In this Issue Articles Mass Spectrometry & Spectroscopy 67th ASMS Conference on Mass Spectrometry and Allied Topics Chromatography Using Gas Chromatography for measuring atmo...

View all digital editions


ACS National Meeting & Expo, Fall 2019

Aug 25 2019 San Diego, CA, USA

Microscopy Conference 2019

Sep 01 2019 Berlin, Germany

BMSS Annual Meeting

Sep 03 2019 Manchester, UK

JASIS 2019

Sep 04 2019 Chiba City, Japan

ICMGP 2019

Sep 08 2019 Krakow, Poland

View all events